lfm-a13 and Immunologic-Deficiency-Syndromes

lfm-a13 has been researched along with Immunologic-Deficiency-Syndromes* in 1 studies

Other Studies

1 other study(ies) available for lfm-a13 and Immunologic-Deficiency-Syndromes

ArticleYear
BCR targets cyclin D2 via Btk and the p85alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells.
    Oncogene, 2003, Apr-17, Volume: 22, Issue:15

    The p85alpha subunit of PI3-K and Btk are two crucial components of the B-cell receptor (BCR) signalling pathway. In the present study, we showed that primary splenic B cells from p85alpha null and xid (Btk-deficient) mice fail to induce cyclin D2 expression and enter early G1, but not S phase of the cell cycle in response to BCR engagement. Furthermore, these Btk or p85alpha null B cells displayed increased cell death compared with wild type following BCR engagement. These findings are further confirmed by studies showing that specific pharmacological inhibitors of Btk (LFM-A13), PI3-K (LY294002 and Wortmannin) and PLCgamma (U73122) also block cyclin D2 expression and S phase entry following BCR stimulation, as well as triggering apoptosis. Collectively, these data provide evidence for the concept that the B-cell signalosome (p85alpha, Btk, BLNK and PLCgamma) is involved in regulating cyclin D2 expression in response to BCR engagement. PKC and intracellular calcium are two major downstream effectors of the B-cell signalosome and can be activated by PMA and ionomycin, respectively. In small resting (G0) B cells, costimulation with PMA and ionomycin, but not PMA or ionomycin alone, induces cyclin D2 expression and cell-cycle progression. Consistent with this, we also showed that the BCR-mediated cyclin D2 induction could be abolished by pretreatment of resting B cells with specific inhibitors of capacitative Ca(2+) entry (SK&F 96365) or PKC (Gö6850). Our present results lead us to propose a model in which the B-cell signalosome targets cyclin D2 via the Ca(2+) and PKC-dependent signalling cascades to mediate cell-cycle progression in response to BCR engagement.

    Topics: Adaptor Proteins, Signal Transducing; Agammaglobulinaemia Tyrosine Kinase; Amides; Animals; Antibodies, Anti-Idiotypic; Apoptosis; B-Lymphocytes; Calcium Signaling; Carrier Proteins; Cell Cycle; Chromones; Class Ib Phosphatidylinositol 3-Kinase; Crosses, Genetic; Cyclin D2; Cyclins; Enzyme Inhibitors; Female; Imidazoles; Immunologic Deficiency Syndromes; Indoles; Ionomycin; Isoenzymes; Macromolecular Substances; Male; Maleimides; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Mutant Strains; Models, Immunological; Morpholines; Nitriles; Phenotype; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phospholipase C gamma; Phosphoproteins; Phosphorylation; Protein Interaction Mapping; Protein Processing, Post-Translational; Protein Subunits; Protein-Tyrosine Kinases; Receptors, Antigen, B-Cell; Signal Transduction; src-Family Kinases; Tetradecanoylphorbol Acetate; Type C Phospholipases

2003